Jörn Schattenberg and GenFit Global Diagnostics Leader Suneil Hosmane join the Surfers to review holistic and patient-centric issues to be covered at the 4th Global NASH Congress.
Roger Green conducts one-on-one interviews with Stephen Harrison and Alina Allen to explore specific issues regarding new issues and insights for clinical research and drug development resulting from the work of Dr. Allen and her colleagues.
The group focuses on the patient treatment implications of being able to identify the patients who are at risk of rapid progression, particularly among those with compensated cirrhosis.
Alina Allen shares the results of her recent Clinical Gastroenterology and Hepatology paper on predictive value of MR Elastography in determining likelihood of progress for NASH patients exhibiting F1 – F3 disease and separately, those living with cirrhosis.
Alina Allen of the Mayo Clinic joins the Surfers to discuss her recent publication demonstrating that kPa scores from MR Elastography can predict the course of disease for non-cirrhotic and cirrhotic patients and consider its implications for clinical trials and every day patient treatment.
Ian Rowe presents more findings from his work in Leeds, revealing paradoxes and complexity in the patient screening process. Listen to this conversations to consider the goals for a therapy that, in Ian’s words, “treats the patient and not the NASH.”
The final conversation of Episode 16 explores possible possible pathways and treatment strategies for NASH therapy in a future world with multiple classes of agents.
Mazen Noureddin joins the Surfers to discuss his work determining the cost-effectiveness of non-invasive NASH testing and treatment in Type 2 diabetics and the broader population. The discussion shifts to considering broader treatment issues.
Surfing the NASH Tsunami closes the book on NASH-TAG 2021 by considering highlights and major themes of the conference. The conversation focuses on the dramatic increase in disease knowledge and drug development over the past year and highlights some specific papers and ideas. A thoughtful, energetic conclusion to a meeting that left much to think about and many reasons to be excited.
Naim Alkhouri and Jörn Schattenberg join Roger and Donna to review the closing session of NASH-TAG 2021, a potpourri of basic science and review of promising drugs earlier in development.
